Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder

Author： Kratochvil Christopher J   Vaughan Brigette S   Harrington Martin J   Burke William J  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.7, 2003-07, pp. : 1165-1174

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder

By Stiefel Gary  

Drug Safety, Vol. 33, Iss. 10, 2010-10 ,pp. : 821-842

Adis International

Access to resources Recommend Favorite

Hepatic Events Associated with Atomoxetine Treatment for Attention-Deficit Hyperactivity Disorder

By Bangs Mark E.   Jin Ling   Zhang Shuyu   Desaiah Durisala   Allen Albert J.   Read Holly A.   Regev Arie   Wernicke Joachim F.  

Drug Safety, Vol. 31, Iss. 4, 2008-01 ,pp. : 345-354

Adis International

Access to resources Recommend Favorite

New drugs for treatment of attention-deficit/hyperactivity disorder

By Chung Bowen   Suzuki Alejandra R   McGough James J  

Expert Opinion on Emerging Drugs, Vol. 7, Iss. 2, 2002-10 ,pp. : 269-276

Informa Healthcare

Access to resources Recommend Favorite

New drugs for the treatment of attention-deficit/hyperactivity disorder

By Pataki Caroly S   Feinberg David T   McGough James J  

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 2, 2004-11 ,pp. : 293-302

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Atomoxetine in Adults with Attention-Deficit Hyperactivity Disorder

By Simpson D.   Plosker G.L.  

CNS Drugs, Vol. 18, Iss. 6, 2004-01 ,pp. : 397-401

Adis International

Access to resources Recommend Favorite